Yondelis® . Un Cáncer Colorrectal Primario en un Modelo de Ratón de Xenoinjerto Ortotópico Derivado del Paciente ... Ha Conseguido ser Detenido con la Combinación de Yondelis ( Trabectedin ) con Oxaliplatino y 5-Fluorouracilo .

Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.

Zhu G, et al. Anticancer Res. November 2019.

Abstract :

BACKGROUND/AIM:

In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model.

MATERIALS AND METHODS:

A patient CRC tumor previously established in nude mice was implanted subcutaneously in transgenic green fluorescence protein (GFP)-expressing nude mice. Harvested tumor fragments were transplanted orthotopically in non-transgenic nude mice. Mice were randomized into three groups: Group 1 (G1), untreated-control; Group 2 (G2), OXA+5-FU; Group 3 (G3), TRAB+OXA+5-FU. Tumor width, length, and mouse body weight were measured twice a week.

RESULTS:

Both treatment groups inhibited tumor growth compared to the untreated control group. The combination of TRAB, OXA and 5-FU was significantly more efficacious than OXA+5-FU and arrested tumor growth. No significant changes were observed in body-weight in any of the three groups.

CONCLUSION:

TRAB, OXA and 5-FU combination has clinical potential for this and other CRC patients.

Copyright© November 2019, International Institute of Anticancer Research (Dr. George J. Delinasios) .